Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Takeda pharmaceutical - The Untold Story

Takeda Pharmaceutical Q4 Earnings Call Highlights

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three expected product launches and a broader cost transformation program. The earnings call also mar

MarketBeat · May 15

What's Going On With Takeda Stock On Friday?

On Friday, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday.

Benzinga · Aug 22, 2025

Why Takeda no longer has an 'IT department' as part of the drug maker's digital and data transformation

Gabriele Ricci, chief data and technology officer, has been reorganizing the technology function at Takeda Pharmaceutical.

Fortune · Nov 13, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Digitalization could be the answer to better health care for patients. But first, they need to trust it

Takeda Pharmaceutical chief digital trust officer Mike Towers says his industry has been slow to adapt, but is accelerating fast.

Fortune · Jul 21, 2023

Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022

Upgrades

Benzinga · Jul 19, 2022

Looking Into Takeda Pharmaceutical's Recent Short Interest

Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which is 0.13% of all regular shares that are available for trading.

Benzinga · Jul 5, 2022

Organisations

Pioneer Natural Resources

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Health Care

3,386 stories

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.